# Uncommon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/uncommon

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.uncommonbio.co
- Total disclosed funding: $30M
- Latest round: Series A (Apr 6, 2023)
- Investors on record: 6

## About

Based in Cambridge, UK, and founded in 2017, Uncommon operates as a biotechnology research firm that develops bacon and pork belly from animal cells. The company was Co-founded by Benjamina Bollag (CEO) and Ruth Faram (Chief scientific officer). In August 2025, Meatable B.V., a portfolio company of DSM Venturing, BlueYard Capital, Backed VC, Section 32, Future Positive Capital, Humboldt Fund, Bridford Investments Ltd., and Betagro Ventures, acquired Uncommon from Balderton Capital, Global Brain, Lowercarbon Capital, and Redalpine. Financial terms of the transaction were not disclosed. The company offers healthy protein and produces meat using cells. It uses a small sample of cells from an animal and makes them grow by nurturing them. The firm develops cells to produce lab-grown pork belly and bacon strips. The acquisition aims to support Meatable’s further development of its capabilities by integrating Uncommon Bio’s non-GMO mRNA reprogramming and saRNA differentiation technologies.

## Funding rounds

- Series A, Apr 6, 2023, $30M — Balderton Capital, Redalpine, Lowercarbon Capital, Dismatrix, Apollo Projects, East X

## Investors

- Balderton Capital (https://capitalatlas.ai/funds/balderton-capital) — Series A
- Redalpine (https://capitalatlas.ai/funds/redalpine) — Series A
- Lowercarbon Capital (https://capitalatlas.ai/funds/lowercarbon-capital) — Series A
- Dismatrix (https://capitalatlas.ai/funds/dismatrix) — Series A
- Apollo Projects (https://capitalatlas.ai/funds/apollo-projects) — Series A
- East X (https://capitalatlas.ai/funds/east-x) — Series A